



# Near Infrared Imaging

**Vein-Eye™**

**Advancing vein illumination to vein visualization**

Michael J. Feeney

President

115 King James Way

Wrentham, MA, 02093

508-384-3800

[michael@nearinfraredimaging.com](mailto:michael@nearinfraredimaging.com)

[www.nearinfraredimaging.com](http://www.nearinfraredimaging.com)

*No offering is made or intended by this document. Any offering of interests in Near Infrared Imaging, LLC, will be made only in compliance with Federal and State securities laws.*

*This document includes non-confidential information of Near Infrared Imaging, LLC. This document is provided for informational purposes only. You may reproduce this document in whole or in part, or divulge its contents, without the prior written consent of Near Infrared Imaging, LLC.*

## Table of Contents

<b>Section</b>	<b>Pages(s)</b>
Company Mission	3
Value proposition - Opportunity and ROI - Funding options	3 & 4
Use of funds	4
Vein-Eye CARRY	4
Vein-Eye CARRY (cont.), Vein-Eye PLUS, Vein-recognition Biometrics and Optical Ultrasound Tomography	4 & 5
NII – Patents - Strategic Partners – Assets	6
NII’s Science and Technology	7
Industry Overview – the Demand for vein illumination	8
Competitive Advantages	9 & 10
Market Analysis – Who will buy	10
Sales Strategy – Business Model	11
Income	12
Exit strategy - ROI	12
Regulatory Concerns	12 & 13
Strengths, Weaknesses, Opportunities and Threats	13 & 14
Management and their capabilities	15
Milestones - Historical and projected – Exit Strategy	16, 17 & 18

## **COMPANY MISSION**

Near Infrared Imaging's mission is to become a worldwide leader in the imaging of the human body using safe, optics-based technology. Near Infrared Imaging (NII) is on the cusp of causing a paradigm shift in medical imaging. NII's patented technologies are revolutionary, life-saving, safe, non radiation, non-contact, non-invasive and affordable to the worldwide population.

Near Infrared Imaging's first product is the Vein-Eye, a vein illumination camera superior to competing products. The Vein-Eye is already selling and generating profits and cash flow.

## **REQUEST**

NII is in search of \$250,000 - \$1,000,000.

## **RETURN ON INVESTMENT**

NII will provide:

- 100,000 non-restricted shares in exchange for \$250,000,
- 200,000 non-restricted shares in exchange for \$500,000,
- 400,000 non-restricted shares in exchange for \$1,000,000.
- Presently, there are 2.75M shares Authorized and 1.8M Outstanding.

## **OPPORTUNITY**

- Locating a vein to insert a needle can be difficult in any patient.
- Locating a vein in people with dark skin, the aged, the very young or the obese can be very difficult and painful.
- The Vein-Eye offers the best optimal solution at the best prices.
- The risks to the investor/partner are limited. And, there is a high likelihood of both near term and long term success.
- The Vein-Eye is FDA registered, has the CE Marking and the Declaration of Conformity.
- NII has the FDA Certificate to Foreign Governments for the Vein-Eye

The use of investment funds are detailed in the accompanying pro-forma:

- Completion of the development of the Vein-Eye CARRY
- Purchase of 300 Vein-Eye CARRY units for inventory
- Purchase of 150 Vein-Eye HC and AU
- Payment of patent maintenance fees and the purchase of IP
- Salaries and commissions to sales and business development consultants
- Advertising, marketing and attendance at trade shows and conferences
- Customer Service operations and 1-800 technical support operations
- Development of the biometrics multi-modal prototype

The Vein-Eye will eventually become the gold standard in vein illumination, while lowering the cost and creating availability worldwide. As NII realizes profits, we will issue dividends to the investors and re-invest to develop other products and technologies:

### **Vein-Eye CARRY**

- There is no product on the market able to be taken into the home by a visiting nurse, EMT, or home health aide.
- There is no product on the market for patients who are taught to self-stick at home.
- There is no lightweight, portable and safe product able to be carried in a small case from room to room, floor to floor, and building to building.
- NII is putting the power of the existing 72 LEDs, that are now in the Vein-Eye HC and AU, on a PCB that is about the size of a Quarter.
- NII is developing a high-powered ring that can increase our LED power equal to 400 LEDs – in about the size of a quarter.
- The new Vein-Eye CARRY will toggle between 760nm and 850nm, as 760nm is ideal for newborns and obese patients.
- NII is working with Videology (<http://www.videologyinc.com/>) to develop the CARRY and TABLET.
- The CARRY – with the TABLET - will be the only portable, lightweight, certified and proven option. It will be less expensive than the existing Vein-Eye, will have a battery, will fit into a nurse's purse, and will be able to be sold from your website.
- The Vein-Eye will become the cell phone of the vein illumination industry

- Once the prototypes are done, NII will immediately file for patent protection on both the method and the apparatus of the Vein-Eye CARRY.
- The CARRY will provide additional features, such as image capture, recording, remote access and will be both wired and wireless.
- The Vein-Eye CARRY will be less expensive and more flexible than any product on the market. It will be the size of the GoPro camera.
- Price is a major factor impacting sales in the largest countries of the world.

### **Vein-Eye PLUS**

The Vein-Eye PLUS will be a robust camera that will travel underneath the veins, providing depth information on the vein. No other light-based system does this.

### **Vein-recognition biometrics**

- Our multi-modal biometric solution images both the fingerprints and the vein patterns in the fingers and the palm - a multi-modal approach.
- NII has had extensive contact and discussion with Samsung, NATO, Dept. of Defense, Medtronic and others regarding this technology.
- This technology will soon be in a mobile device.
- Since NII is owned in part by the NSA and Dept. of Energy, we will have immediate access to the FBI, CIA, Homeland security, Dept. of Defense and civilian and military markets.

### **Optical Ultrasound Tomography™ (OUT).**

- OUT will cause a paradigm shift in medical imaging.
- The PAT 2700 - will detect bleeding in the brain at the scene of the injury.
- The healthcare professional will be able to quickly triage which patient needs immediate surgery and which patient can be monitored and treated.
- The PAT 2700 will also perform continuous monitoring of the patient at the bedside.

## COMPANY

Near Infrared Imaging (NII) incorporated in 2009 as an LLC, merged into a Delaware INC, is a “Corporation In Good Standing” with the Commonwealth of Massachusetts and has filed and paid all of its Federal and State taxes every year. Near Infrared Imaging has a pre-money valuation of \$5M and is owned in part by:

- The Regents of the University of California (UCLA)
- The City University of New York (CUNY)
- Lawrence Livermore National Laboratory (LLNL)
  - NII is the first, and only, commercial company that LLNL has taken partial ownership in.

<b>Exclusive rights, options and trademarks</b>	<b>Filing Date</b>	<b>Expires</b>	<b>Authority</b>
NII has exclusive rights to the Vein-Eye PLUS patent #US 8,586,924 B2	09/13/2010	11/19/2030	<b>APPROVED</b> - USPTO - 11-19-2013
NII has exclusive rights to the method of illuminating veins: City University of New York - #9,529,443	07/27/1999	12/15/2016	<b>APPROVED</b> - USPTO the process of illuminating veins
NII has exclusive rights to Vein-Eye apparatus patent application: US2014/204675 A1	12/12/2014	03/15/2035	US patent approval pending - NII and LLNL have filed for PCT
NII was granted the Optical Ultrasound Tomography™ Trademark	07/17/2014	2031	<b>APPROVED</b> - Published in the Trademark Official Gazette (OG)
NII was granted the Vein-Eye™ Trademark	07/17/2014	2034	<b>APPROVED</b> USPTO - 04/2015
NII has an option for the exclusive rights to LLNL’s non-contact vein-recognition biometrics technology	09/16/2014	12/16/2015	LLNL Agreement AL00144-0.0
NII has exclusive rights to Optical Ultrasound Tomography™. USPTO Patent application number: US/2012/028944 and PCT application WO 2012 125649 A2	03/13/2012	2032	LLNL and NII signed an agreement giving NII exclusive rights and have jointly applied to the USPTO and to the PCT.

## SCIENCE AND TECHNOLOGY

The Vein-Eye technology is based upon the principle of the polarization and depolarization of light to detect objects below the surface of a scattering medium such as human tissue, water and smoke. This technology has been highlighted in over 250 research articles.

The method technology is based upon work done by Dr. Stavros Demos and Doctor Alfano at the City University of New York (CUNY). The Vein-Eye was developed by Dr. Demos of Lawrence Livermore National Laboratory. An apparatus patent was filed in 2013 by Lawrence Livermore National Laboratory.

Our technology images and enhances visualization of near-surface vascular structures. The near infrared light illuminates the blood in the veins and also focuses on objects, such as small tumors, located under surface of the human body. The light is backscattered from the surface of the human tissue and, using an array of patented optical enhancement methods, the light that interacted with the veins is enhanced to make the veins far more visible than viewing with the naked eye.

- Ultrasound technology to illuminate veins is successful when imaging deep veins and arteries. Ultrasound is not as successful when imaging veins near the surface as it requires contact with the skin. Ultrasound equipment costs are in excess of \$15,000.
- The Vein-Eye technology uses conventional imaging sensors and LEDs. The camera can be anywhere from 6 inches to 5 feet away from the patient.
- NII will offer the Vein-Eye in a wireless format, CARRY, Tablet, adjunct module to a smart-phone, and in GLASSES. The Vein-Eye can be fit to be worn on night-vision goggles by the military.
- The leading-selling vein illumination device uses lasers, in the 50mW range. We believe that the Federal laser safety regulations require both the healthcare professional and the patient to have protective eyewear when this is in use.
- The Vein-Eye uses safe LEDs, similar to holiday lights.
- The Vein-Eye is robust and practically unbreakable.
- The NII – BIO will be a non-contact, light based, vein-recognition biometrics technology using the unique patterns of your veins in your fingers and palm.
- Using a light transmission technique, the structure of the vein pattern can be detected, captured and subsequently verified.

## THE DEMAND

The sales launch began with no fanfare in October, 2014. To date, we have shipped products to distributors in thirty (30) countries.

Vein illumination is a multi-million dollar industry that is experiencing tremendous demand and rapid growth. By visualizing the veins of a patient, medical practitioners will be able to avoid anxiety, pain to the patient, treatment delays, and infection.

- When a medical practitioner or nurse inserts a needle for an IV or to draw blood, it should be accomplished in a timely and safe manner.
- Vein illumination is important in every needle insertion, but it is paramount when the patient is obese, very young, aged and/or has dark skin.
- There are over 2,700,000 needle sticks every day in the USA and 20,000,000 – 40,000,000 every day worldwide. .

The research demonstrates a need for vein illumination.

- Care delays occur in approximately 25 percent of all patients regardless of care setting due to the inability to establish IV access.
- IV placement estimate range from one in three attempts resulting in failure in adults, and one in two attempts resulting in failure in pediatrics. **That translates to 50% failure in pediatrics.**
- **Industry forecasts are that “image guidance systems” will increase the success rate of IV placements in difficult patients by 50-80%.**
- This will translate to a savings in time, and materials, of up to \$1,250 for every 100 IV starts.
- Success rate and time to vascular cannulation are crucial to the optimal resuscitation of a critically-ill patient.
- This can be a challenging to even the most experienced emergency healthcare professional.
- The failure rate of puncturing a vein in critically ill patients ranges from 10% to 40%.

The importance of these findings is even greater based on the 2012 Affordable Care Act. Medicare now takes into consideration a patient’s well being and level of satisfaction when reimbursing the hospital.



## COMPETITIVE ADVANTAGES

- 1) The MSRP of the #1 selling vein illumination device is above \$6,000 with the hospital cart.
- 2) The Vein-Eye AU has an MSRP of \$2,199 and the Vein-Eye HC (hospital cart) has an MSRP of \$2,499.
- 3) The Vein-Eye illumination is provided by totally safe LEDs.
- 4) In contrast, the competition uses lasers which represent a risk of accidental exposure and injury to the eyes.
- 5) The leading-selling device uses 50 mW laser power. Based on the laser classification scheme, this is a class 3B laser device.
- 6) The laser classification scheme also states: "Protective eyewear is typically required where direct viewing of a class 3B laser beam may occur."

“Due to the increased power levels, these lasers are a real, immediate and often unrecognized danger. While seen as a novelty, or a “bigger is better” solution, **a laser emitting 50 mW or more can immediately cause an injury upon exposure, permanently affecting eyesight.** Children and adults alike have suffered permanent partial blindness because they do not recognize that there is an immediate danger.”  
*The Unrecognized Dangers of New Laser Pointers, Laser Institute of America, News, /By Michelle, on July 26th, 2011*

- 7) Please view this video. <https://www.youtube.com/watch?v=sZVEPUkzySY>  
AccuVein uses the AV400 to image veins in the face. Note the use of protective shield for the eyes because it is used on the face. Then, how can they insure there will be no accidental exposure to an adult, child or infant?
- 8) The Vein-Eye successfully passed the arduous and expensive IEC 60601 3<sup>rd</sup> edition testing at Intertek. This includes:
  - a. EMI (electrical interference) and EMC (electrical safety) testing, Product Safety testing, and the IEC 60601 3<sup>rd</sup> edition Risk Management File (in excess of 300 pages).
- 9) Our competitors have not submitted their product for this testing, which will become mandatory in 2016 and is already mandatory in many countries in the EU.
- 10) The Vein-Eye performs significantly better than the competition when the patient has hair on the arm or hand.

- 11) The leading selling device cannot image through hair.
- 12) Competing devices project the image back onto the arm on a 4” by 4” area.
- 13) The Vein-Eye uses a monitor which can display the entire arm in one image, showing a runway image, important for IV placement.
- 14) Other devices, using lasers, cause a bright red or green glare that is difficult to use for long periods of time.
- 15) The competing devices have very plastic looking images. Every vein looks the same: depth, width, and size.
- 16) With the Vein-Eye, you can see the differences in the veins and can tell which ones are closer to the surface, and which ones are larger or slightly deeper

**INDUSTRY ANALYSIS: MARKET SIZE – WHO WILL BUY**

Every country will quickly adopt our technology. The top 15 most populous countries, plus the UK, Spain, France and Canada, will be our first targets.

Country	Population	No. of hospitals	No. of physicians	No. of clinics
China	1.3B	30,000	1, 4000,000	310,000
India	1.1B	15,000	600,000	274,000
USA	307M	5,700	800,000	22,500
Indonesia	229M	1,039	100,000	5,000
Brazil	191M	7,500	127,000	40,000
Pakistan	167M	12,000	110,000	N/A*
Bangladesh	162M	1,683	71,129	N/A
Nigeria	154M	6,000	23,000	N/A
Russia	141M	12,000	690,000	N/A
Japan	127M	9,100	260,000	N/A
Mexico	107M	2,300	150,000	N/A
Philippines	92M	2,068	260,484	N/A
Vietnam	85M	200	54,400	N/A
Germany	82M	2,260	270,600	N/A
Ethiopia	79M	115	1,936	412

In the top 15 most populous countries, there are approximately 107,000 hospitals, 4,500,000 physicians, and 500,000 medical clinics.

**In a recent study published by the Oxford Journal, African, Asian, elderly and obese patients were associated with decreased vein visibility.**

“In China, as people are living longer and the elderly population continues to rise, market demand for healthcare and rehabilitation products is fast expanding. At present, companies in China selling home medical and rehabilitation products on the mainland are growing at 20% - 100% a year. Hence, the trend of using healthcare and rehabilitation products at home will become more and more common.” - *HKTDC Research*

According to the United Nations, China’s population is ageing and that by the year 2025, there will be 300 million people aged 60 and over in China.

## **SALES STRATEGY – PATHWAY TO SUCCESS – OPPORTUNITY FOR THE DISTRIBUTOR**

NII is signing authorized resellers/distributors that have a history of success. The response from both international and domestic distributors has exceeded our expectations. By using qualified authorized resellers, NII has hundreds of sales people representing our products.

- Authorized resellers have the option of maintaining a minimal stocking inventory or of using our manufacturer to stock inventory.
- They are responsible for Tier 1 technical support.
- Their costs of goods from NII will be dependent upon annual sales.
- They are required to purchase a small inventory initially.
- NII offers exclusive territories with a significant initial purchase.
- The profit margins for the Distributor are in the 30 – 50-% range.

The biggest market could eventually be the patient’s home, as the worldwide trend in medicine is to stay in the hospital as little as possible.

**“According to a survey by FIND/SVP Inc’s Advanced Analytics division, the home testing kit market is worth \$4.5 billion. For example, even with the high number of blood pressure monitors all ready in the market place, each year over 8 million new blood pressure-monitoring devices are sold.”**

**INCOME (Costs, MSRP and profits per unit for the Vein-Eye CARRY are not yet been finalized. The numbers below will change, but not the profit per device to NII.)**

NII's cost of goods per camera: \$700 - \$850  
MSRP: \$2,199 - \$2,499  
Resellers' margin per unit sold: \$600 - \$1,000  
Net profit per camera to NII: \$400 - \$600

The cost of the Vein-Eye will decrease over time.

### **Forecast**

<b>Year</b>	<b>Unit Sales</b>	<b>Total Revenue</b>	<b>NII's Profits</b>
<b>2015</b>	<b>1,000</b>	<b>\$1.5M</b>	<b>\$500K</b>
<b>2016</b>	<b>7,500</b>	<b>\$10.5M</b>	<b>\$5.25M</b>
<b>2017</b>	<b>15,000</b>	<b>\$22M</b>	<b>\$11M</b>
<b>2018</b>	<b>30,000</b>	<b>\$44M</b>	<b>\$22M</b>
<b>2019</b>	<b>70,000</b>	<b>\$80M</b>	<b>\$40M</b>

### **EXIT STRATEGY**

The Company is looking for an early exit strategy. It is NII's goal to develop the safest and highest quality products, introduce them onto the worldwide market, and then sell them to larger companies so that they are available and affordable to the worldwide community. NII is amenable to going public.

Every investor has the right to sell their shares to NII, another investor, an employee, or an outside source. This right, and the procedure for doing this, is detailed in NII's incorporation documents under Shareholder Agreement.

### **REGULATORY CONCERNS**

- The Vein-Eye is registered with the FDA.
- Our contract manufacturer is ISO 13485 and ISO 9001 certified.
- The Vein-Eye has passed the rigorous IEC 60601 3<sup>rd</sup> edition testing by Intertek, a global leader in testing medical devices.
- The Vein-Eye has a Declaration of Conformity and the CE Marking.

Our contract manufacturer is a highly rated and high quality manufacturer. From their website:

**“Sparqtron is an ISO 9001 & 13485 certified and FDA registered medical device contract manufacturing company. We have been a contract manufacturer of medical device for more than 10 years. We are committed to maintain full compliance with regulatory requirements.**

- The Vein-Eye has successfully passed the IEC 6061 3<sup>rd</sup> Edition certification.
- The Vein-Eye has the CE Marking and required Declaration of Conformity.
- The Declaration of Conformity is on file.
- A Certificate of Origin is on file.
- The Vein-EYE has GTIN and UPC numbers and barcodes.
- A Letter of Authorization is on file.

## **STRENGTHS, WEAKNESSES, OPPORTUNITIES, THREATS**

### **Strengths**

- The leading-selling device company used \$13M - \$15M to get to the point where NII is today.
- NII has used \$900,000 to get t this point, less than 10% of the leading selling device company used.
- NII is in discussions with large international distributors who want to resell the Vein-Eye.
- NII has recently met with Samsung, the Dept. of Defense, Medtronic, Phillips, and other large companies regarding our biometrics and OUT technologies.
- They have all told us to build the devices, conduct data on the success of the technologies, and to re-engage with them.
- Our scientists are some of the brightest in optical imaging, lasers, and photoacoustic imaging.
- Total amount of company debt is less than \$150,000.
- There is no software or microprocessor in the Vein-Eye.

- The areas of potential fault are limited.
- NII will use the profits to fund the development of other technologies which will cause a paradigm shift in medical imaging and provide a very significant return on investment, year after year.
- Vein Visualization will decrease medical costs by limiting the costs of infection and additional needle stick attempts. And, guided vein punctures are reimbursed at a greater rate than non-guided vein punctures.
- NII's products do not infringe on competing technology.
- The vein illumination industry is still in its infancy, with a tremendous amount of upside.

### **Weaknesses**

- NII requires funding to jumpstart the launch of the Vein-Eye.
- Our competitors have a 3-4 year lead.
- NII requires funding to begin the development of the Vein-Eye PLUS, biometrics and Optical Ultrasound Tomography/

### **Opportunities**

- This is a tremendous opportunity for the investor or partner to get in on the ground floor.
- The interest from distributors worldwide has exceeded our forecast.
- Many of these distributors are interested in private labeling the Vein-Eye.

### **Threats**

- NII is unaware of any legal, business, or technology threat to our company.

## **MANAGEMENT TEAM**

### **Michael Feeney, President**

Michael has a B.S. and an M.S. from Northeastern University, Boston, MA. He has spent twenty (20) years in optical networking, with over fifteen (15) years in optics in medicine. In 1993, he was awarded “Employee of the Year” for Fujitsu Network Switching, a division of Fujitsu Limited. .

### **Mikhail Fridberg, MSEE**

Mikhail has an MSEE from the Institute of Radiotechnics and Telecomm, St. Petersburg, Russia. He is experienced in all phases of hardware projects including requirements definition, system design, specification, component design and implementation. His recent projects have included Control Systems design, Embedded FW design, DSP hardware and software design, Algorithm Development using Matlab and Simulink, Analog and mixed-mode design and the development of medical devices.

### **Dr. Neel Madan, MD, Neuroradiologist**

Dr. Madan is a Neuroradiologist and Assistant Professor, Tufts University School of Medicine, Boston, MA. His specialty is pediatrics and he has a strong interest in reviewing and understanding new developments in imaging. He graduated from New York Medical College and is board certified in Radiology. He recently wrote an article on “New directions in clinical imaging of cortical dysplasias.”

[http://www.tuftsmedicalcenter.org/OurServices/Radiology/Neel\\_Madan](http://www.tuftsmedicalcenter.org/OurServices/Radiology/Neel_Madan)

### **Doctor Ryan Abbott, Legal and Medical Consultant**

Ryan has an MD and JD and is an Assistant Professor at the David Geffens School of Medicine at UCLA. <http://www.drryanabbott.com/>

### **Fred Hammett, Senior Business Development Consultant**

Fred graduated from the University of New Mexico and spent 18 years with Hewlett-Packard as a Regional Sales Manager, introducing Ultrasound, Fetal Monitoring, Computer EKG, Computer Monitoring Systems and Oxygen Saturation.

### **James Hoffecker, Field Engineering Manager**

James has extensive experience working as a Lead Field Service Engineer with knowledge of Nuclear Medical Imaging, X-rays, and pharmaceuticals.

## Strategic Partners

Videology Imaging Solutions

<http://www.videologyinc.com/>

Videology is presently working on the Vein-Eye CARRY and Vein-Eye Tablet. They have a very dedicated and talented staff of optical and camera experts. They have recently been given the mission by their CEO to finish the development of the new product line.

Sunburst EMS

<http://www.sunburstems.com/>

Sunburst is working with NII to complete the Vein-Eye CARRY and Vein-Eye Tablet. Sunburst is a ISO 13485 certified manufacturer.

## Historical Milestones

2009	Purchased exclusive rights to a patent for the imaging of intracranial hematomas. The patent was developed at UCLA's Medical School.
2010	Received first investments and loans.
2010	Met Dr. Stavros Demos, and Dr. Alexander Rubenchik, at Lawrence Livermore National Laboratory. Agreed to work on the concept of non-contact photoacoustic imaging for the real-time imaging of bleeding in the brain using optical imaging and ultrasound.
2010	Began hiring consultants to search for funding.
2010	LLNL filed patent application for the Vein-Eye PLUS, a new method of detecting veins and small tumors below the surface of the skin.
2011	Continued work with LLNL on non-contact photoacoustic imaging for the detection of bleeding in the brain in real-time and at the scene of the injury. Labeled the technology Optical Ultrasound Tomography and filed for Trademark.
2012	LLNL and NII filed for international patent protection for Optical Ultrasound Tomography.
2013	Merged Near Infrared Imaging LLC into Near Infrared Imaging Inc.
2013	Hired and trained a domestic team of business development consultants to identify, qualify and enlist investors, scientists, and strategic partners for the Optical Ultrasound Tomography, Vein-Eye and vein-recognition biometrics.



2013	Purchased from the City University of New York (CUNY) the exclusive rights to using near infrared light to detect and illuminate veins and objects below the surface of the skin. This is the method technology for the Vein-Eye.
2013	Formed a partnership with Sparqtron Corp. to develop the Vein-Eye in conjunction with LLNL.
2013	Signed contracts with LLNL on the exclusive rights to the Vein-Eye PLUS and Optical Ultrasound Tomography.
2014	Completed work on the Vein-Eye product and engaged Intertek Testing Laboratory for the testing and certification. The Vein-Eye successfully passed the rigorous IEC 60601 3 <sup>rd</sup> edition testing after 6 months and over 400 pages of a Risk Management File.
2014	LLNL and NII filed for patent protection on the Vein-Eye apparatus.
2014	LLNL and NII filed for domestic and international patent protection for their vein-recognition biometrics technology.
2014	Hired and trained both a domestic and international team of business development consultants to identify, qualify and enlist authorized distributors.
2014	Received Trademark from the USPTO for the Vein-Eye™
2014	Released the Vein-Eye Hospital Cart (HC) and the Vein-Eye Attached Unit (AU) for sales to qualified investors.
2015	Received the USPTO Trademark for Optical Ultrasound Tomography™
2015	Developed the system requirements for the Vein-Eye CARRY.
2015	Began the development of the Vein-Eye CARRY with consultants and potential strategic partners Videology, Sunburst EMS, and Sparqtron.

### Projected Milestones

2015	Obtain funding.
2015	Increase sales, distribution capabilities, advertisement and marketing of the Vein-Eye worldwide.
2015	Complete development of the Vein-Eye CARRY.
2015	Complete UL, CSA and Intertek testing and certification of the CARRY and release it for sales and distribution.
2015	File for patent protection domestically and internationally for the Vein-Eye CARRY, Tablet and Smart-phone.
2015	Hire and train James Hoffecker as NII's Technical Support Manager
2015	Hire a Director of Technology.
<b>(17)</b>	

2015	Market the CARRY to the Visiting Nurse Association, Walgreens, CVS and other pharmaceutical and medical equipment facilities in the USA.
2015	Use the success in the USA with the VNA, Walgreens and CVS to spread the “portable, inexpensive, safe and lightweight” Vein-Eye CARRY concept worldwide.
2015	Develop the Vein-Eye Tablet and Vein-Eye Smart-phone, using Google, Apple or Samsung
2016	Hire sales, marketing, administrative, and other necessary personnel required to successfully grow the business.
2016	Sign strategic partnership agreements or licensing agreements for the Vein-Eye HC, AU, CARRY, Tablet and Smart-phone with large international medical equipment distributors and manufacturers. Pursue strategic partnerships with Samsung and Google.
2016	Begin development of the Vein-Eye PLUS
2016	Use profits from the Vein-Eye sales to provide aggressive dividends to the investors, with the goal that, by 2016, all investors will have recovered the amount of their initial investments.
2016	Hire technical staff to complete the development of vein-recognition biometrics.
2016	License the vein-recognition biometrics technology to a strategic partner such as Raytheon, Lockheed Martin, Google, Samsung or Apple.
2016	Begin development of Optical Ultrasound Tomography
2016	Complete the development, testing and certification of the Vein-Eye PLUS.
2017	Continue paying investors aggressive dividends.
2017	Complete the development, testing, and certification of Optical Ultrasound Tomography for the detection of bleeding in the brain.
2017	Begin testing of Optical Ultrasound Tomography for use with brain illnesses and brain diseases.
2017	Secure a partner, or partners, for acquisition or merger.
2017	Initiate a new IPO or complete a reverse merger into a clean Shell on the NASDAQ.